Clinical Trials

KRASG12C Inhibitor Adagrasib (MRTX849)

Sponsored by Mirati

Study 849-001:
Phase 1/2 study of MRTX849 in patients with cancer having a KRASG12C mutation (KRYSTAL-1)
Study 849-002:
Phase 1/2 study of MRTX849 in combination with TNO-155 in patients with cancer having a KRASG12C mutation (KRYSTAL-2)
Study 849-007:
Phase 2 trial of adagrasib monotherapy and in combination with pembrolizumab and a phase 3 trial of adagrasib in combination in patients with a KRASG12C mutation (KRYSTAL-7)
Study 849-010:
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in patients with CRC with KRASG12C mutation (KRYSTAL-10)
Study 849-012:
Phase 3 study of MRTX849 vs docetaxel in patients with NSCLC with KRASG12C mutation (KRYSTAL-12)
Study 849-017:
Combination therapies with adagrasib in patients with advanced NSCLC with KRASG12C mutation
Study 849-019:
Adagrasib in combination with nab-sirolimus in patients with advanced solid tumors and non-small cell lung cancer with a KRASG12C mutation (KRYSTAL-19)
Study 849-021:
Trial of two adagrasib dosing regimens in NSCLC With KRASG12C mutation (KRYSTAL 21)

Adagrasib collaborative trials are run by Zai Lab, Sanofi, Novartis, Boehringer Ingelheim, respectively.

MTA-Cooperative PRMT5 Inhibitor (MRTX1719)

Sponsored by Mirati

Study 1719-001:
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

SOS1 (MRTX0902)

Sponsored by Mirati

Study 0902-001:
Phase 1/2 Study of MRTX0902 in Solid Tumors with Mutations in the KRAS-MAPK Pathway

KRASG12D Inhibitor (MRTX1133)

Study 1133-001:
Phase 1/2 Study of MRTX1133 in Solid Tumors Harboring a KRASG12D Mutation

This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.

To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator